Internal Server Error

Ncardia - About the company

Ncardia is a series C company based in The Hague (Netherlands), founded in 2011 by Stefan Braam. It operates as a Company offering hiPSC based products and services for drug discovery and development. Ncardia has raised $77.4M in funding from investors like Vesalius Biocapital Partners, Epimede and Kiniciti. The company has 88 active competitors, including 28 funded and 2 that have exited. Its top competitors include companies like Pandorum, InSphero and Newcells Biotech.

Company Details

Ncardia, formed by the merger of Pluriomics and Axiogenesis in 2017, is a stem-cell based drug discovery and development services provider specializing in offering hiPSC (human induced Pluripotent Stem Cells) based products and services. Both the companies were providers of human cardiovascular stem cell technology, disease modeling and cell-based assay products and services for cardiovascular drug development at the time of the merger. The company also offers its services for cardiovascular and neural safety and efficacy studies. The company has offices in Belgium, the Netherlands, Germany, and the USA. Their product portfolio includes cardiac cells (hiPSC-derived), cardiac fibroblasts, neural cells (includes pan-neuronal cells, astrocytes and peripheral neurons) and cardiac plates (ready-to-use assay plates).
Social
XFacebook
Email ID
*****@ncardia.com
Registered Address
Rue Edouard Belin 2 1435 Mont-Saint-Guibert
Key Metrics
Founded Year
2011
Location
The Hague, Netherlands
Stage
Series C
Total Funding
$77.4M in 6 rounds
Latest Funding Round
Ranked
Employee Count
42 as on Aug 31, 2026
Similar Companies
Sign up to download Ncardia's company profile

Ncardia's funding and investors

Ncardia has raised a total funding of $77.4M over 6 rounds. Its first funding round was on Oct 24, 2014. Its latest funding round was a Series C round on Nov 16, 2021 for $*****. 1 investor participated in its latest round. Ncardia has 11 institutional investors.

Here is the list of recent funding rounds of Ncardia:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Nov 16, 2021
4803555
Series C
1017591
7854760
7659004
1256965
Feb 01, 2020
2264335
Grant (prize money)
7460847
5744030
2280961
Jan 01, 2020
1938543
Grant (prize money)
6143494
8190906
6215364
lockAccess funding benchmarks and valuations. Sign up today!

Ncardia's founders and board of directors

Founder? Claim Profile
The founders of Ncardia is Stefan Braam.
Here are the details of Ncardia's key team members:

Ncardia's employee count trend

Ncardia has 42 employees as of Aug 26. Here is Ncardia's employee count trend over the years:
Employee count trend for Ncardia
lockUncover Ncardia's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Ncardia's Competitors and alternates

Top competitors of Ncardia include Pandorum, InSphero and Newcells Biotech. Here is the list of Top 10 competitors of Ncardia, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Pandorum
Pandorum
2011, Bengaluru (India), Series B
Developer of regenerative medicine and 3D tissues
$52.1M
65/100
2nd
Logo for InSphero
InSphero
2009, Schlieren (Switzerland), Series D
Developer of cell based assays for drug screening
$35M
62/100
3rd
Logo for Ncardia
Ncardia
2011, The Hague (Netherlands), Series C
Company offering hiPSC based products and services for drug discovery and development
$77.4M
61/100
4th
Logo for Newcells Biotech
Newcells Biotech
2014, Newcastle Upon Tyne (United Kingdom), Series B
Developer of induced pluripotent stem cells derived organoid models for research application
$14.4M
59/100
5th
Logo for Parallel Bio
Parallel Bio
2020, Cambridge (United States), Series A
Limited information available
$25.4M
54/100
6th
Logo for HeartBeat
HeartBeat
2021, Vienna (Austria), Seed
Developer of stem-cell derived organoid models for cardiac drug discovery
$6.58M
53/100
7th
Logo for Nextandbio
Nextandbio
2019, Seoul (South Korea), Series A
Provider of organoid technology to develop customized treatments for patients
$5.27M
48/100
8th
Logo for BioDimension
BioDimension
2021, Bengaluru (India), Seed
Developer of biofabricating human tissues and organoids to make research
$983K
44/100
9th
Logo for SUN bioscience
SUN bioscience
2015, Lausanne (Switzerland), Funding Raised
Provider of 3D cell culture systems for personalized medicine and organoid research
-
44/100
10th
Logo for NEXEL
NEXEL
2012, Seoul (South Korea), Series B
Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids
$27M
42/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Ncardia's competitors? Click here to see the top ones

Ncardia's Investments and acquisitions

Ncardia has made no investments or acquisitions yet.

Reports related to Ncardia

Here is the latest report on Ncardia's sector:

News related to Ncardia

lockFilter this list
•
Ncardia Appoints Andy Holt as Chief Commercial OfficerBusiness Wire•Feb 24, 2022•Ncardia
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Ncardia

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford